Summary
LIBRA PHARMA is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €1.2m and a net result of €137,007. Equity is growing by ~12.4% per year across the filed fiscal years. Its solvency ranks better than 34% of 5565 sector peers (fiscal year 2025). The company has been active since 2011 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Outside the general model
Model not applicable to financial institutions
The Checked score weighs liquidity, leverage and margins against norms for trading and manufacturing companies. A bank, insurer or financial holding has a fundamentally different balance-sheet structure, so those ratios, and hence the score, carry no meaning here. That is why we show no financial axes either.
Credit check for your own amount and term
Open the credit simulator : see how the verdict changes with amount, term and advance.
Signals
1 signal. The signal on the left, the evidence on the right.
○neutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 07-07-2026, 24 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
24 d early
2024
on the day
2023
30 d late
2022
31 d late
2021
60 d late
2020
31 d late
2019
52 d late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 26 days after the deadline; the sector median for financial year 2024 is 14 days before the deadline, and 28% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
27-09-2026 today31-12-2026 close31-07-2027 deadline
History
Go further with this company
How much credit can you give this customer, and on what term?Credit simulator What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What changed in the latest annual accounts?What changed Is the workforce growing, and do people stay?Employer check
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, abbreviated schema
Equity
€1.2m▲ 13.0%
2024 · €1.1m
Net result
€137,007▲ 215%
2024 · €43,462
Total assets
€3.6m▲ 117%
2024 · €1.6m
Solvency
33.3%▼ 30.7pp
2024 · 64.0%
Trend over the years
Click a name to add, emphasise or remove a line.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20212022202320242025
Operating result€246,254▲ 51.3%€238,308▼ 3.2%€80,382▼ 66.3%€65,103▼ 19.0%€107,820▲ 65.6%
Net result€143,359▲ 70.1%€144,233▲ 0.6%€52,308▼ 63.7%€43,462▼ 16.9%€137,007▲ 215%
Equity€811,063▲ 21.5%€955,296▲ 17.8%€1.0m▲ 5.5%€1.1m▲ 4.3%€1.2m▲ 13.0%
Total assets€1.7m▲ 5.8%€1.7m▲ 0.2%€1.7m▼ 2.7%€1.6m▼ 2.2%€3.6m▲ 117%
Debt€910,268▼ 5.2%€770,103▼ 15.4%€672,029▼ 12.7%€591,834▼ 11.9%€2.4m▲ 302%
Working capital-€382,865▼ 105%-€309,631▲ 19.1%-€355,226▼ 14.7%-€400,115▼ 12.6%-€586,677▼ 46.6%
Solvency47.1%▲ 6.1pp55.4%▲ 8.2pp60.0%▲ 4.6pp64.0%▲ 4.0pp33.3%▼ 30.7pp
Staff (FTE)0.8
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result recovers in 2025; 2025 is 66% above 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €3.6m
Fixed assets
€3.5m ▲ 134%
Current assets
€113,071 ▼ 33.0%
Equity and liabilities €3.6m
Equity
€1.2m ▲ 13.0%
Debt
€2.4m ▲ 302%
Debt's share of the balance-sheet total rises from 36.0% to 66.7%. Equity and debt are higher.
Key figures and ratios
ROE
11.5%▲
2024 · 4.1%
ROA
3.8%▲
2024 · 2.6%
Debt ≤ 1 year
€699,747▲
2024 · €568,998
Debt > 1 year
€1.7m▲
2024 · €22,426
Income taxes
€33,526▲
2024 · €22,333
Staff costs
€51,858
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Remuneration, social security and pensions62 | - | - | - | - | €51,858 | - |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €105 | €2,371 | €3,072 | €3,512 | €13,599 | ▲ 287% |
| Other operating charges640/8 | €1,789 | €2,197 | €2,126 | €2,545 | €4,773 | ▲ 87.6% |
| Gross operating margin9900 | €248,148 | €242,875 | €85,579 | €71,160 | €178,051 | ▲ 150% |
| Operating profit (loss)9901 | €246,254 | €238,308 | €80,382 | €65,103 | €107,820 | ▲ 65.6% |
| Financial income75/76B | €935 | €5,187 | €9,785 | €8,200 | €104,491 | ▲ 1,174% |
| Recurring financial income75 | €935 | €5,187 | €9,785 | €8,200 | €104,491 | ▲ 1,174% |
| Financial charges65/66B | €35,155 | €29,778 | €10,760 | €7,508 | €41,778 | ▲ 456% |
| Recurring financial charges65 | €35,155 | €29,778 | €10,760 | €7,508 | €41,778 | ▲ 456% |
| Profit (loss) for the period before taxes9903 | €212,033 | €213,717 | €79,407 | €65,795 | €170,533 | ▲ 159% |
| Income taxes67/77 | €68,674 | €69,485 | €27,099 | €22,333 | €33,526 | ▲ 50.1% |
| Profit (loss) for the period9904 | €143,359 | €144,233 | €52,308 | €43,462 | €137,007 | ▲ 215% |
| Profit (loss) for the period to be appropriated9905 | €143,359 | €144,233 | €52,308 | €43,462 | €137,007 | ▲ 215% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €1.7m | €1.7m | €1.7m | €1.6m | €3.6m | ▲ 117% |
| Fixed assets21/28 | €1.5m | €1.5m | €1.5m | €1.5m | €3.5m | ▲ 134% |
| Tangible fixed assets22/27 | €4,328 | €5,218 | €4,682 | €4,639 | €82,811 | ▲ 1,685% |
| Plant, machinery and equipment23 | - | €1,620 | €904 | €3,111 | €2,229 | ▼ 28.4% |
| Furniture and vehicles24 | €4,328 | €3,597 | €3,778 | €1,527 | €7,555 | ▲ 395% |
| Leasing and similar rights25 | - | - | - | - | €73,026 | - |
| Financial fixed assets28 | €1.5m | €1.5m | €1.5m | €1.5m | €3.4m | ▲ 129% |
| Current assets29/58 | €247,625 | €250,804 | €205,573 | €168,884 | €113,071 | ▼ 33.0% |
| Amounts receivable within one year40/41 | €225,527 | €225,724 | €164,890 | €142,994 | €106,085 | ▼ 25.8% |
| Trade receivables40 | €137,752 | €45,140 | €19,250 | €16,335 | €50,752 | ▲ 211% |
| Other amounts receivable41 | €87,776 | €180,585 | €145,640 | €126,659 | €55,333 | ▼ 56.3% |
| Cash at bank and in hand54/58 | €20,163 | €23,318 | €38,712 | €24,350 | €4,502 | ▼ 81.5% |
| Deferred charges and accrued income490/1 | €1,935 | €1,762 | €1,971 | €1,540 | €2,483 | ▲ 61.2% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €1.7m | €1.7m | €1.7m | €1.6m | €3.6m | ▲ 117% |
| Equity10/15 | €811,063 | €955,296 | €1.0m | €1.1m | €1.2m | ▲ 13.0% |
| Contributions10/11 | €12,400 | €12,400 | €12,400 | €12,400 | €12,400 | = |
| Reserves13 | €792,821 | €937,054 | €989,362 | €1.0m | €1.2m | ▲ 13.8% |
| Non-distributable reserves130/1 | €1,860 | €1,860 | €0 | - | - | - |
| Reserves not available under the articles1311 | €1,860 | €1,860 | €0 | - | - | - |
| Distributable reserves133 | €790,961 | €935,194 | €989,362 | €1.0m | €1.2m | ▲ 13.8% |
| Profit (loss) carried forward14 | €5,842 | €5,842 | €5,842 | €5,842 | €0 | ▼ 100% |
| Amounts payable17/49 | €910,268 | €770,103 | €672,029 | €591,834 | €2.4m | ▲ 302% |
| Amounts payable after more than one year17 | €279,437 | €196,179 | €110,540 | €22,426 | €1.7m | ▲ 7,343% |
| Financial debts170/4 | €279,437 | €196,179 | €110,540 | €22,426 | €1.7m | ▲ 7,343% |
| Amounts payable within one year42/48 | €630,490 | €560,435 | €560,799 | €568,998 | €699,747 | ▲ 23.0% |
| Current portion of amounts payable after more than one year42 | €80,968 | €83,258 | €85,639 | €88,114 | €147,397 | ▲ 67.3% |
| Financial debts43 | - | - | - | - | €2,381 | - |
| Credit institutions430/8 | - | - | - | - | €2,381 | - |
| Trade debts44 | €7,098 | €1,773 | €2,117 | €1,917 | €9,357 | ▲ 388% |
| Suppliers440/4 | €7,098 | €1,773 | €2,117 | €1,917 | €9,357 | ▲ 388% |
| Taxes, remuneration and social security45 | €19,463 | €15,105 | €5,170 | €9,204 | €75,090 | ▲ 716% |
| Taxes450/3 | €19,463 | €15,105 | €5,170 | €9,204 | €52,927 | ▲ 475% |
| Remuneration and social security454/9 | - | - | - | - | €22,163 | - |
| Other amounts payable47/48 | €522,961 | €460,299 | €467,873 | €469,762 | €465,521 | ▼ 0.9% |
| Accrued charges and deferred income492/3 | €341 | €13,489 | €690 | €410 | €8,655 | ▲ 2,011% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €143,359 | €144,233 | €52,308 | €43,462 | €137,007 | ▲ 215% |
| + Depreciation and write-downs630 | €105 | €2,371 | €3,072 | €3,512 | €13,599 | ▲ 287% |
| Operating cash flow (approximation) | €143,465 | €146,603 | €55,380 | €46,974 | €150,606 | ▲ 221% |
| Investment in fixed assets (approximation) | - | -€3,260 | -€2,536 | -€3,469 | -€2.0m | ▼ 57,319% |
| Change in cash | - | €3,155 | €15,394 | -€14,362 | -€19,847 | ▼ 38.2% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
07-07
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
31-07
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
31-12
Financial
Weakest financial yearnet €43,462 ▼16.9%
Net result drops to €43,462, the lowest in the series; recovery starts the following year.
30-08
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema · 30 days late
2023
31-12
Financial
Equity above €1mEq €1.0m ▲5.5%
6 profitable years in a row build equity to €1.0m.
31-08
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema · 31 days late
2022
31-12
Financial
Highest result since 2018net €144,233 ▲0.6%
Net result €144,233, the highest in the series.
29-09
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema · 60 days late
2021
31-08
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema · 31 days late
2020
21-09
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema · 52 days late
2019
01-07
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
28-06
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2017
13-07
NBB filing
Annual accounts filed
fiscal year 2016 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 4 acts read
About the unread acts
We know of 4 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
4 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Boechout · 1 establishment unit since 2011
Ground area
1,152 m²
Building footprint
243 m²
Volume, LiDAR
284 m³
Parcel 11047B0067/00P003, Flanders · tallest building 7.7 m. Linked by address, not a title deed.
2
companies at this address
See who is registered here
1 establishment unit
Libra Pharma
since 20112.196.649.528
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 11047B0067/00P003 | Flanders | 1,152 m² | 1 · 243 m² | 7.7 m |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Structure & network
Owners and holdings
2 holdingsOwners 0
The accounts to 31-12-2025 list no shareholders, and no other source names one.
Holdings 2
-
100%
-
100%
According to the 2025 annual accounts of LIBRA PHARMA and those of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
No current directors or connected companies found in the register.
Similar companies · same sector, comparable size
GRYP JIMMY
BE 0635.687.916
Assenede · Eq €1,187,848
ANFI
BE 0447.279.569
Brugge · Eq €1,187,893
HUZAAR HOLDING
BE 1005.073.616
Deinze · Eq €1,187,906
Urbis Vastgoedgroep
BE 0741.668.631
Gent · Eq €1,187,354
CONTWEN
BE 0442.549.929
Hoegaarden · Eq €1,187,169
Of 24,729 companies in sector 64210 we hold annual accounts for 19,773. 12,288 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded16-02-2011
Fiscal year end31-12
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
64210Activities of holding companies
E-invoicing
Reachable via Peppol
Peppol ID
0208:0833903555
Also
9925:BE0833903555
Registered
18-09-2026
Register as of 27 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.